Enanta Pharmaceuticals, Inc. (ENTA): Price and Financial Metrics


Enanta Pharmaceuticals, Inc. (ENTA): $47.27

0.36 (+0.77%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ENTA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ENTA POWR Grades


  • Value is the dimension where ENTA ranks best; there it ranks ahead of 70.5% of US stocks.
  • ENTA's strongest trending metric is Growth; it's been moving down over the last 179 days.
  • ENTA's current lowest rank is in the Growth metric (where it is better than 10.93% of US stocks).

ENTA Stock Summary

  • Of note is the ratio of Enanta Pharmaceuticals Inc's sales and general administrative expense to its total operating expenses; merely 6.07% of US stocks have a lower such ratio.
  • ENTA's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 8.2% of US stocks.
  • With a year-over-year growth in debt of 122.86%, Enanta Pharmaceuticals Inc's debt growth rate surpasses 91.52% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Enanta Pharmaceuticals Inc, a group of peers worth examining would be RVMD, PTGX, SYRS, INO, and ALPN.
  • Visit ENTA's SEC page to see the company's official filings. To visit the company's web site, go to www.enanta.com.

ENTA Valuation Summary

  • In comparison to the median Healthcare stock, ENTA's price/sales ratio is 213.16% higher, now standing at 11.9.
  • Over the past 103 months, ENTA's price/sales ratio has gone up 7.7.
  • Over the past 103 months, ENTA's EV/EBIT ratio has gone down 18.3.

Below are key valuation metrics over time for ENTA.

Stock Date P/S P/B P/E EV/EBIT
ENTA 2021-08-31 11.9 2.8 -13.8 -12.5
ENTA 2021-08-30 11.8 2.7 -13.7 -12.4
ENTA 2021-08-27 11.7 2.7 -13.5 -12.2
ENTA 2021-08-26 11.2 2.6 -13.0 -11.8
ENTA 2021-08-25 11.1 2.6 -12.9 -11.6
ENTA 2021-08-24 11.0 2.6 -12.8 -11.6

ENTA Growth Metrics

    Its 3 year price growth rate is now at 258.81%.
  • Its year over year cash and equivalents growth rate is now at 3.72%.
  • Its year over year revenue growth rate is now at -46.46%.
ENTA's revenue has moved down $141,005,000 over the prior 34 months.

The table below shows ENTA's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 92.979 -68.377 -100.783
2021-09-30 97.074 -69.996 -78.996
2021-06-30 97.13 -64.436 -83.738
2021-03-31 94.159 -39.418 -73.979
2020-12-31 101.646 -20.165 -57.939
2020-09-30 122.473 7.088 -36.168

ENTA's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ENTA has a Quality Grade of C, ranking ahead of 57.4% of graded US stocks.
  • ENTA's asset turnover comes in at 0.206 -- ranking 196th of 682 Pharmaceutical Products stocks.
  • GILD, ALT, and RDUS are the stocks whose asset turnover ratios are most correlated with ENTA.

The table below shows ENTA's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.206 1 -0.234
2021-03-31 0.193 1 -0.207
2020-12-31 0.204 1 -0.157
2020-09-30 0.242 1 -0.083
2020-06-30 0.296 1 -0.048
2020-03-31 0.354 1 0.017

ENTA Price Target

For more insight on analysts targets of ENTA, see our ENTA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $65.33 Average Broker Recommendation 1.7 (Moderate Buy)

ENTA Stock Price Chart Interactive Chart >

Price chart for ENTA

ENTA Price/Volume Stats

Current price $47.27 52-week high $102.00
Prev. close $46.91 52-week low $37.59
Day low $45.57 Volume 238,800
Day high $48.32 Avg. volume 250,115
50-day MA $49.57 Dividend yield N/A
200-day MA $65.51 Market Cap 979.10M

Enanta Pharmaceuticals, Inc. (ENTA) Company Bio


Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses a chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. The company was founded in 1995 and is based in Watertown, Massachusetts.


ENTA Latest News Stream


Event/Time News Detail
Loading, please wait...

ENTA Latest Social Stream


Loading social stream, please wait...

View Full ENTA Social Stream

Latest ENTA News From Around the Web

Below are the latest news stories about Enanta Pharmaceuticals Inc that investors may wish to consider to help them evaluate ENTA as an investment opportunity.

Open Orphan client Enanta Pharmaceuticals confirms positive results from human challenge study - DirectorsTalk Interviews

Open Orphan client Enanta Pharmaceuticals confirms positive results from human challenge study

DirectorsTalk | February 17, 2022

Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938 for the Treatment of Respiratory Syncytial Virus (RSV)

WATERTOWN, Mass., February 17, 2022--Enanta Pharmaceuticals Announces Publication in The New England Journal of Medicine of Data from the Phase 2a Human Challenge Study of EDP-938

Yahoo | February 17, 2022

Enanta Pharma Commences Dosing In Phase 1 COVID-19 Trial

Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) has dosed the first subject in its Phase 1 trial of EDP-235 , a coronavirus 3CL protease inhibitor, specifically designed as a once-daily, oral treatment for COVID-19. The Company plans to report data from this study in Q2 of 2022, and, assuming positive findings, Enanta expects to advance EDP-235 to the … Full story available on Benzinga.com

Benzinga | February 16, 2022

Enanta begins dosing of oral COVID-19 therapy EDP-235 in phase 1 trial

Enanta Pharmaceuticals (ENTA) dosed the first person in its phase 1 trial of its oral COVID-19 therapy EDP-235.The phase 1 study will evaluate the EDP-235 in single ascending…

Seeking Alpha | February 16, 2022

Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

WATERTOWN, Mass., February 16, 2022--Enanta Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Designed for the Treatment of COVID-19

Yahoo | February 16, 2022

Read More 'ENTA' Stories Here

ENTA Price Returns

1-mo 17.53%
3-mo -34.14%
6-mo -36.79%
1-year 5.75%
3-year -44.21%
5-year 31.38%
YTD -36.79%
2021 77.62%
2020 -31.85%
2019 -12.78%
2018 20.71%
2017 75.16%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5489 seconds.